Virtu Financial LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 66.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,300 shares of the medical research company's stock after selling 10,274 shares during the period. Virtu Financial LLC's holdings in IQVIA were worth $1,256,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of IQV. Simplify Asset Management Inc. increased its position in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares during the period. Raymond James & Associates grew its holdings in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock worth $169,231,000 after acquiring an additional 5,417 shares during the period. Versor Investments LP bought a new position in shares of IQVIA in the 3rd quarter worth approximately $1,328,000. Gradient Investments LLC boosted its position in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock valued at $9,600,000 after purchasing an additional 6,134 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its position in shares of IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company's stock valued at $62,501,000 after purchasing an additional 8,490 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have commented on IQV. Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. BTIG Research lowered their price target on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Robert W. Baird cut their price objective on shares of IQVIA from $213.00 to $212.00 and set a "neutral" rating on the stock in a report on Wednesday. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $256.19.
Read Our Latest Stock Report on IQV
IQVIA Stock Performance
Shares of NYSE IQV traded down $1.31 during trading on Friday, reaching $199.06. 1,135,902 shares of the company traded hands, compared to its average volume of 1,186,062. The firm has a 50 day simple moving average of $212.86 and a 200-day simple moving average of $224.44. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market capitalization of $36.13 billion, a PE ratio of 26.12, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.